WT1 peptide vaccination for patinets with hematological CR after induction chemotherapy
Phase 1
- Conditions
- Cancer vaccine
- Registration Number
- JPRN-UMIN000017937
- Lead Sponsor
- Cancer immunotherapy of Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1. double cancer 2. active infections 3. autoinflamatory disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie WT1 peptide vaccination in hematological cancer immunotherapy?
How does WT1 peptide vaccination compare to standard-of-care treatments for hematological cancers in phase I trials?
Which biomarkers are associated with response to WT1 peptide vaccination in hematological CR patients?
What adverse events are reported in WT1 peptide vaccination phase I trials and how are they managed?
Are there combination therapies or competitor drugs for WT1-targeted cancer vaccines in hematological malignancies?